Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P,a Portable Next-Generation Dermal Electroporation Device
Restricted accessResearch articleFirst published online August, 2015
Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P,a Portable Next-Generation Dermal Electroporation Device
The CELLECTRA-3P dermal electroporation device (Inovio Pharmaceuticals, Plymouth Meeting, PA) has been evaluated in the clinic and shown to enhance the delivery of an influenza DNA vaccine. To understand the mechanism by which this device aids in enhancing the host immune response to DNA vaccines we investigated the expression kinetics and localization of a reporter plasmid (pGFP) delivered via the CELLECTRA-3P. Histological analysis revealed green fluorescent protein (GFP) expression as early as 1 hr posttreatment in the epidermal and dermal layers, and as early as 2 hr posttreatment in the subdermal layers. Immunofluorescence techniques identified keratinocytes, fibrocytes, dendritic-like cells, adipocytes, and myocytes as the principal cell populations transfected. We proceeded to demonstrate elicitation of robust host immune responses after plasmid DNA (pDNA) vaccination. In guinea pigs equivalent humoral (antibody binding titers) immune responses were observed between protocols using either CELLECTRA-3P or intramuscular electroporation to deliver the DNA vaccine. In nonhuman primates, robust interferon-γ enzyme-linked immunospot and protective levels of hemagglutination inhibition titers after pDNA vaccination were observed in groups treated with the CELLECTRA-3P. In conclusion, these findings may assist in the future to design efficient, tolerable DNA vaccination strategies for the clinic.
Get full access to this article
View all access options for this article.
References
1.
TobinDJ. Biochemistry of human skin—our brain on the outside. Chem Soc Rev, 2006; 35:52–67.
2.
ToebakMJ, GibbsS, BruynzeelDP, et al.Dendritic cells: biology of the skin. Contact Dermatitis, 2009; 60:2–20.
3.
NickoloffBJ, TurkaLA, MitraRS, et al.Direct and indirect control of T-cell activation by keratinocytes. J Invest Dermatol, 1995; 105:25S–29S.
4.
WeinerDB. DNA vaccines: crossing a line in the sand [introduction to special issue]. Vaccine, 2008; 26:5073–5074.
5.
DonnellyJJ, UlmerJB, and LiuMA. DNA vaccines. Life Sci, 1997; 60:163–172.
6.
AndreS, SeedB, EberleJ, et al.Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol, 1998; 72:1497–1503.
7.
SardesaiNY, and WeinerDB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol, 2011; 23:421–429.
8.
MartinonF, KaldmaK, SikutR, et al.Persistent immune responses induced by a human immunodeficiency virus DNA vaccine delivered in association with electroporation in the skin of nonhuman primates. Hum Gene Ther, 2009; 20:1291–1307.
9.
SongJM, KimYC, LipatovAS, et al.Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice. Clin Vaccine Immunol, 2010; 17:1381–1389.
10.
MathiesenI. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther, 1999; 6:508–514.
11.
OttenG, SchaeferM, DoeB, et al.Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine, 2004; 22:2489–2493.
12.
OttenGR, SchaeferM, DoeB, et al.Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine, 2006; 24:4503–4509.
13.
Prud'hommeGJ, Draghia-AkliR, and WangQ. Plasmid-based gene therapy of diabetes mellitus. Gene Ther, 2007; 14:553–564.
14.
WideraG, AustinM, RabussayD, et al.Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol, 2000; 164:4635–4640.
15.
MirLM, and OrlowskiS. The basis of electrochemotherapy. Methods Mol Med, 2000; 37:99–117.
16.
OrlowskiS, BelehradekJJr., PaolettiC, et al.Transient electropermeabilization of cells in culture: increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol, 1988; 37:4727–4733.
17.
KopycinskiJ, CheesemanH, AshrafA, et al.A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers. Clin Vaccine Immunol, 2012; 19:1557–1559.
18.
DiazCM, ChiapporiA, AurisicchioL, et al.Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med, 2013; 11:62.
19.
ChudleyL, McCannK, ManderA, et al.DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time. Cancer Immunol Immunother, 2012; 61:2161–2170.
20.
VasanS, HurleyA, SchlesingerSJ, et al.In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One, 2011; 6:e19252.
21.
BagarazziML, YanJ, MorrowMP, et al.Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med, 2012; 4:155ra138.
22.
BroderickKE, ShenX, SoderholmJ, et al.Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Ther, 2011; 18:258–265.
23.
RoosAK, ErikssonF, TimmonsJA, et al.Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One, 2009; 4:e7226.
24.
RoosAK, MorenoS, LederC, et al.Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther, 2006; 13:320–327.
25.
El-KamarySS, BillingtonM, DeitzS, et al.Safety and tolerability of the Easy Vax clinical epidermal electroporation system in healthy adults. Mol Ther, 2012; 20:214–220.
26.
HiraoLA, WuL, KhanAS, et al.Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine, 2008; 26:440–448.
27.
LaddyDJ, YanJ, KhanAS, et al.Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol, 2009; 83:4624–4630.
28.
HiraoLA, Draghia-AkliR, PriggeJT, et al.Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis, 2010; 203:95–102.
29.
DiehlMC, LeeJC, DanielsSE, et al.Tolerability of intramuscular and intradermal delivery by CELLECTRA® adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother, 2013; 9:2246.
30.
MendozaJM, AmanteDH, KichaevG, et al.Elucidating the kinetics of expression and immune cell infiltration resulting from plasmid gene delivery enhanced by surface dermal electroporation. Vaccines, 2013; 1:384–397.
31.
SmithTRF, SchultheisK, KiossesWB, et al.DNA vaccination strategy targets epidermal dendritic cells, initiating their migration and induction of a host immune response. Mol Ther Methods Clin Dev, 2014; 1:14054.
32.
YanJ, CorbittN, PankhongP, et al.Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine. Vaccine, 2011; 29:7173–7181.
33.
KalamsSA, ParkerSD, ElizagaM, et al.Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis, 2013; 208:818–829.
34.
LinF, ShenX, KichaevG, et al.Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device. Hum Gene Ther Methods, 2012; 23:157–168.
35.
HellerLCJ, CoppolaMJ, McCrayD, et al.Optimization of cutaneous electrically mediated plasmid DNA delivery using novel electrode. Gene Ther, 2007; 14:275–280.
36.
RoosAK, ErikssonF, WaltersDC, et al.Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol Ther, 2009; 17:1637–1642.
37.
GronevikE, Von SteyernFV, KalhovdeJM, et al.Gene expression and immune response kinetics using electroporation-mediated DNA delivery to muscle. J Gene Med, 2005; 7:218–227.
38.
HutnickNA, MylesDJ, BianCB, et al.Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol, 2011; 1:233–240.
